```html

Yellow Eyes (Jaundice) – A Complete Medical Guide

Overview

Jaundice is a clinical sign characterized by a yellow‑pigmented discoloration of the skin, sclera (the white part of the eyes), and mucous membranes. The yellow hue results from an accumulation of bilirubin, a yellow‑orange pigment produced when red blood cells break down.

Jaundice is not a disease itself; it is a symptom of an underlying problem with bilirubin production, transport, metabolism, or excretion. It can affect people of any age, but the most common causes differ between newborns, children, adults, and the elderly.

Prevalence: In the United States, an estimated 2 – 5 % of adults develop clinically evident jaundice each year, while up to 60 % of newborns experience some degree of physiological jaundice within the first week of life (CDC, 2023). Worldwide, liver diseases that cause jaundice—including hepatitis, alcoholic liver disease, and non‑alcoholic fatty liver disease (NAFLD)—affect > 1 % of the global population (WHO, 2022).

Symptoms

Jaundice presents with a spectrum of signs that may develop slowly or appear abruptly, depending on the cause.

• Scleral icterus (yellow eyes) – often the first visible sign because the conjunctiva is thin and richly vascularized.
• Yellow skin – most noticeable on the face, neck, and the palms/soles.
• Dark urine – bilirubin that is excreted into the urine turns it amber or brown.
• Light‑colored (pale) stools – indicates reduced bilirubin reaching the intestines.
• Pruritus (itching) – bile salts deposited in the skin can cause intense itching.
• Fatigue and weakness – especially with chronic liver disease.
• Abdominal pain or fullness – may suggest gallstones or hepatitis.
• Nausea, vomiting, loss of appetite – common in hepatic inflammation.
• Weight loss – in progressive liver disease or pancreatic cancer.
• Fever and chills – when jaundice is due to infection (e.g., cholangitis).
• Confusion or altered mental status (hepatic encephalopathy) – a late sign of severe liver failure.

Causes and Risk Factors

Primary Mechanisms

Bilirubin accumulates for three main reasons:

1. Pre‑hepatic (hemolytic) jaundice – excessive breakdown of red blood cells releases more unconjugated bilirubin than the liver can process.
2. Hepatic (parenchymal) jaundice – liver cells are damaged and cannot conjugate or secrete bilirubin effectively.
3. Post‑hepatic (obstructive) jaundice – blockage of bile flow prevents conjugated bilirubin from reaching the intestine.

Common Causes

• Newborn physiological jaundice – immature liver enzymes, common in the first 5‑7 days of life.
• Hemolytic anemia (e.g., sickle cell disease, G6PD deficiency, autoimmune hemolysis).
• Viral hepatitis A, B, C, D, E – inflammation damages hepatocytes.
• Alcoholic liver disease – chronic alcohol intake leads to steatosis, hepatitis, and cirrhosis.
• Non‑alcoholic fatty liver disease (NAFLD) and non‑alcoholic steatohepatitis (NASH) – linked to obesity, diabetes, and dyslipidemia.
• Drug‑induced liver injury – acetaminophen overdose, certain antibiotics, anti‑TB meds, statins.
• Bile duct obstruction – gallstones, pancreatic head tumor, cholangiocarcinoma, primary sclerosing cholangitis.
• Genetic disorders – Gilbert syndrome (mild, often asymptomatic), Crigler‑Najjar syndrome (severe, rare), Dubin‑Johnson and Rotor syndromes (conjugated hyperbilirubinemia).
• Sepsis or septic cholangitis – bacterial infection of the biliary tree.

Risk Factors

• Heavy alcohol consumption (≥ 14 drinks/week for men, ≥ 7 for women).
• Obesity (BMI ≥ 30 kg/m²) and metabolic syndrome.
• Chronic viral hepatitis infection.
• Family history of hereditary bilirubin metabolism disorders.
• Medication use that is hepatotoxic.
• Gallstone disease (more common in females, age > 40, obesity, rapid weight loss).
• Pregnancy (intra‑hepatic cholestasis of pregnancy).
• Blood transfusion or hemolytic diseases.

Diagnosis

Clinical Evaluation

• History – onset, progression, associated symptoms, alcohol use, medication list, travel, family history.
• Physical exam – assessment of scleral icterus, skin color, abdominal tenderness, hepatomegaly, splenomegaly, ascites.

Laboratory Tests

Test	What It Shows
Serum bilirubin (total, direct, indirect)	Distinguishes unconjugated vs. conjugated hyperbilirubinemia.
Alanine aminotransferase (ALT) & Aspartate aminotransferase (AST)	Hepatocellular injury.
Alkaline phosphatase (ALP) & Gamma‑glutamyl transferase (GGT)	Cholestasis or biliary obstruction.
Complete blood count (CBC)	Detects hemolysis (low hemoglobin, high reticulocyte count).
Coagulation profile (PT/INR)	Liver synthetic function.
Serum albumin	Chronic liver disease indicator.
Viral serologies (HBsAg, anti‑HBc, anti‑HCV, HAV IgM)	Identify hepatitis infection.

Imaging Studies

• Abdominal ultrasound – first‑line to evaluate gallstones, biliary dilation, liver texture.
• CT scan or MRI – for complex biliary or pancreatic pathology.
• Magnetic resonance cholangiopancreatography (MRCP) – non‑invasive bile‑duct visualization.
• Endoscopic retrograde cholangiopancreatography (ERCP) – diagnostic + therapeutic (stone removal, stenting).

Special Tests

• Liver biopsy – indicated when chronic liver disease etiology is unclear.
• Genetic testing – for suspected hereditary syndromes (e.g., Gilbert, Crigler‑Najjar).
• Haptoglobin, lactate dehydrogenase (LDH) – support hemolysis evaluation.

Treatment Options

General Principles

Treatment targets the underlying cause, reduces bilirubin levels, and protects liver function. Supportive care (hydration, nutrition) is essential.

Specific Therapies

• Newborn physiological jaundice
  • Phototherapy – blue‑light converts bilirubin to water‑soluble isomers that can be excreted without conjugation.
  • Exchange transfusion – reserved for bilirubin > 20 mg/dL or signs of acute bilirubin encephalopathy.
• Hemolytic causes
  • Stop offending drugs, treat infections, give steroids or immunosuppressants for autoimmune hemolysis.
  • Folic acid supplementation.
  • Transfusion in severe anemia.
• Viral hepatitis
  • Hepatitis B – antiviral agents (entecavir, tenofovir).
  • Hepatitis C – direct‑acting antivirals (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) with cure rates > 95 %.
  • Supportive care for acute hepatitis A/E (hydration, rest).
• Alcoholic or NAFLD/NASH liver disease
  • Alcohol cessation programs, counseling, medications (e.g., naltrexone, baclofen).
  • Weight loss ≥ 7‑10 % body weight improves NASH histology.
  • Vitamin E (800 IU/day) for non‑diabetic NASH (per AASLD guidelines).
• Biliary obstruction
  • ERCP with stone extraction or stent placement.
  • Surgical cholecystectomy for symptomatic gallstones.
  • Management of cholangiocarcinoma – surgery, chemotherapy, or radiotherapy.
• Drug‑induced liver injury
  • Immediate discontinuation of the offending agent.
  • N‑acetylcysteine for acetaminophen overdose (effective even up to 24 h post ingestion).
  • Monitoring of liver enzymes until normalization.
• Genetic syndromes
  • Gilbert syndrome – usually no treatment; avoid fasting, dehydration, and certain drugs (e.g., irinotecan).
  • Crigler‑Najjar type I – liver transplant is curative; phototherapy as bridge.

Lifestyle & Supportive Measures

• Adequate hydration – helps renal excretion of bilirubin.
• Balanced diet rich in fruits, vegetables, lean protein; limit saturated fat and simple sugars.
• Avoid alcohol and hepatotoxic over‑the‑counter meds (e.g., high‑dose acetaminophen).
• Vaccinations – hepatitis A and B immunization for at‑risk individuals.

Living with Yellow Eyes (Jaundice)

Daily Management Tips

• Monitor bilirubin trends – keep a log of lab results and any changes in skin/eye color.
• Skin care – use mild moisturizers; avoid hot showers that can worsen itching.
• Pruritus relief – antihistamines (cetirizine), cholestyramine resin, or topical calamine.
• Nutrition – small, frequent meals; consider medium‑chain triglyceride (MCT) oil if fat malabsorption is present.
• Physical activity – moderate exercise (150 min/week) aids weight control and improves liver health.
• Medication adherence – use a pill organizer; communicate any new OTC drugs to your provider.
• Regular follow‑up – schedule liver function tests every 3‑6 months or as directed.
• Support networks – patient groups (American Liver Foundation, Hepatitis C Support) provide emotional and practical help.

When Adjustments Are Needed

If you notice worsening yellowing, new abdominal pain, a sudden drop in urine output, or increasing fatigue, contact your clinician promptly. Adjustments in medication doses or additional imaging may be required.

Prevention

• Vaccinate against hepatitis A and B.
• Practice safe sex and avoid sharing needles to reduce hepatitis transmission.
• Limit alcohol – follow CDC guidelines (< 14 drinks/week for men, < 7 for women).
• Maintain a healthy weight – BMI < 25 kg/m² lowers NAFLD risk.
• Stay hydrated – adequate fluid intake supports bilirubin clearance.
• Use medications wisely – read labels, avoid unnecessary acetaminophen (> 4 g/day), and discuss herbal supplements with a doctor.
• Routine health checks – annual liver enzyme panels for high‑risk individuals (e.g., diabetics, heavy drinkers).

Complications

If the underlying cause of jaundice is not addressed, several serious complications may arise:

• Acute bilirubin encephalopathy (kernicterus) – especially in newborns with bilirubin > 20 mg/dL, leading to irreversible neurologic damage.
• Chronic liver failure – progression to cirrhosis, portal hypertension, ascites, variceal bleeding.
• Hepatocellular carcinoma – risk rises with chronic hepatitis B/C or cirrhosis (up to 3‑5 % annual incidence).
• Coagulopathy – impaired synthesis of clotting factors causing easy bruising or bleeding.
• Pruritus‑related sleep disturbance – severe itching can affect quality of life and mental health.
• Vitamin‑A and D deficiencies – malabsorption of fat‑soluble vitamins in cholestatic disease.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Jaundice.” 2023; CDC. “Neonatal Jaundice.” 2023; WHO. “Global Hepatitis Report.” 2022; NIH. “Non‑Alcoholic Fatty Liver Disease.” 2024; Cleveland Clinic. “Bilirubin Metabolism.” 2022; AASLD Guidelines for NAFLD and NASH, 2023; American College of Gastroenterology. “Management of Gallstone Disease.” 2023.

```